- Stage
- In committee
- Started in
- Senate
- Sponsors
- 3
- Latest action
- Jul 15, 2025
What it does
The ETHIC Act would limit patent holders to asserting no more than one patent per "Patent Group" in infringement actions against applicants or holders of approved drug or biological product applications, or against those making, using, selling, or importing such products. It aims to address patent thickets by restricting multiple patent assertions from commonly owned patents linked through disclaimers filed to overcome obviousness-type double patenting rejections. The provision applies to applications submitted for drug or biological product approval on or after the Act’s enactment date.
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.